Trial Profile
Comparison of the Effect of Denosumab and Alendronate on Bone Density and Microarchitecture in Rheumatoid Arthritis Females With Low Bone Mass: A Randomized Controlled Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Alendronic acid
- Indications Osteoporosis
- Focus Therapeutic Use
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 29 Jan 2013 New trial record